Launches

Alvotech has ticked off all of the remaining patent-related matters for its aflibercept biosimilar, with multiple market entries expected in 2026.

As Dr Reddy’s delivered results for its financial third quarter, the firm revealed a slew of updates for key biosimilars in its pipeline including filing and launch plans for abatacept in the US and Europe, as well as US setbacks on rituximab and denosumab.

BMS will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company.

BMS tells Scrip it will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company

Hikma has launched its Enoby and Xtrenbo denosumab biosimilars to Amgen’s Prolia and Xgeva into the competitive US market. How will the firm fare against so many other rivals?

European CNS specialist rolls out a value-added methylphenidate and a first-to-market guanfacine generic as it sharpens its European ADHD strategy.

Civica kept its promise to market its insulin glargine and Stelara biosimilars at the start of the new year.

2025 saw star products debut in India as foreign firms doubled down on high-value, IP-protected therapies. Experts tell Scrip the top 10 cities in the country can now sustain “US/EU-style” specialty launches.

Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.

Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.

Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.

In a busy year for US biosimilars, more than a dozen approvals were seen as multiple brands faced competition for the first time – including Stelara. However, concerns persist over the “biosimilar void”, with hope that the latest FDA announcement on regulatory streamlining can help to fill the gap.